INCOR- Heart Institute
São Paulo, 05403900, Brazil
NCT Number: NCT05877235
Chronic coronary syndrome (CCS) is the leading cause of death in women in the most developed regions of Brazil. The primary etiopathogenic mechanism is the process of atherosclerosis. A healthy diet rich in fruits and vegetables is associated with a lower incidence of CCS. The higher consumption of these foods promotes greater availability of phenolic compounds, and the higher intake of these compounds is one of the main hypotheses for vascular health. Quercetin, a phenolic compound, is the most abundant natural antioxidant belonging to the group of flavonoids. Quercetin improves lipoprotein metabolism, has an antioxidant capacity, produces vasodilating substances in the vascular endothelium, and reduces platelet aggregability. Likewise, statins are medications known to reduce cardiovascular events in women with CCS by reducing serum LDL-cholesterol levels and, to a lesser extent, by possible pleiotropic effects. In turn, SIRT1 is one of the 7 classes of proteins. It mediates various metabolic pathways in response to nutritional stimuli, particularly for caloric restriction and phenolic compounds, as well as coordinating the production and secretion of important hormones. However, the impact of quercetin supplementation and statin administration on serum endogenous estrogen levels is unknown
Looking for future studies?
Notify Me55 year–70 year
Female
Interventional
Not applicable
São Paulo, 05403900, Brazil
The main objective of this study is to investigate the influence of atorvastatin and of quercetin in the serum concentrations of estradiol and estrone after the administration of atorvastatin and supplementation with quercetin. This is a randomized, double-blind, placebo-controlled, 60-day study in 60 postmenopausal women with CAD, divided into three groups of 20 women each: Group 1 - quercetin (500 mg/day); Group 2 - atorvastatin (80 mg/day); Group 3 - control (placebo).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Trans-quercetin, 1000 mg daily for 60 days
Starch, 1000 mg daily for 60 days
Time frame: 60 days
serum concentrations
Time frame: 60 days
serum concentrations
Time frame: 60 days
Serum concentrations and gene expression
Time frame: 60 days
Lipid and glucometabolic profiles
InCor Heart Institute
Other
Serum Concentration of Endogenous Estrogens and Sirtuin-1 in Postmenopausal Women With Atherosclerotic Coronary Heart Disease After Administration of Atorvastatin and Supplementation With Quercetin: a Randomized Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06508437
Arterial Occlusive Diseases, Arteriosclerosis
Tours, France
View Trial DetailsNCT03875651
Arterial Occlusive Diseases, Arteriosclerosis
New Haven, Connecticut, United States
View Trial DetailsNCT04807439
Arterial Occlusive Diseases, Arteriosclerosis
New Haven, Connecticut, United States
View Trial DetailsNCT00500617
Angina Pectoris, Arterial Occlusive Diseases
Anchorage, Alaska, United States
View Trial Details